1Kikuoka S,Shimojo N,Yamaguchi KI,et al. The formation of thyrotropin receptor (TSHR) antibodies in a Graves' animal model requires the N-terminal segment of the TSHR extracellular domain.Endocrinology,1998,139:1891-1898 .
2Chen CR,Tanaka K,Chazenbalk GD,et al.A full biological response to autoantibodies in Graves' disease requires a disulfide-bonded loop in the thyrotropin receptor N terminus homologous to a laminin epidermal growth factor-like domain.J Biol Chem,2001,276:1
3Martin A,Nakashima M,Zhou A,et al.Detection of major T cell epitopes on human thyroid stimulating hormone receptor by overriding immune heterogeneity in patients with Graves' disease. Clin Endocrinol Metab,1997,82:3361-3366.
4Minich WB,Loos U.Detection of functionally different types of pathological autoantibodies against thyrotropin receptor in Graves' patients sera by luminescent immunoprecipitation analysis.Exp Clin Endocrinol Diabetes,2000,108:110-119.
5Tomer YI,Barbesino G,Keddache M,et al.Mapping of a major susceptibility locus for Graves' disease(GD-l) to chromosome 14q31. J Clin Endocrinol Metab,l997,82:l645-l648.
6Kim TY,Park YJ,Park do J,et al.Epitope heterogeneity of thyroid-stimulating antibodies predicts long-term outcome in Graves' patients treated with antithyroid drugs.J Clin Endocrinol Metab,2003,88:117-124.
7Sugawa H,Ueda Y,Ueda M,et al.Immunization with the ""immunogenic peptide"" of TSH receptor induces oligoclonal antibodies with various biological activities.Peptides,1998,19:1303-1307.
9Vlase H,Weiss M,Graves PN,et al.Characterization of the murine immune response to the murine TSH receptor ectodomain:induction of hypothyroidism and TSH receptor antibodies.Clin Exp Immunol,1998,113:111-118.
10Grasso YZ,Kim MR,Faiman C,et al. Epitope heterogeneity of thyrotropin receptor-blocking antibodies in Graves' patients as detected with wild-type versus chimeric thyrotropin receptors.Thyroid,1999,9:531-537.
5Mizutori Y, Chen CR, MeLachlan SM, et al. The thyrotrepin receptor hinge region is not simply a scaffold for the Leueine - Rich Domain but contributes to ligand binding and signal transduction. Molecular Endocrinology. 2008,22(5) :1171.
6Kohn LD, Harii N. Thyrotropin receptor autoantibodies (TSHRAbs) : epitopes, origins and clinical significance. Autoimmunity. 2003,36(6 -7) :331.
7Morgenthaler NG, Ho SC, Minich WB. Stimulating and blocking TSH - receptor autoantibodies from patients with Graves's disease and antoimmune hypothyroidsm have very similar concentration, TSH - receptor affinity and binding sites. J Clin Endocrinol Metab. 2007,92(3 ) :1058.
8Costagliola S, Morgenthaler NG, Hoermann R, et al. Second generation assay for thyrotropin receptor antibodies has superior diagnostic sensitivity for Graves's disease. J Clin Endocrinol Metab. 1999,84(1) :90.
9Villata D, Orunesu E, Tozzoli R, et al. Analytical and diagnostic accuracy of "second generation" assays for thyrotropin receptor antibodies with radioactive and chemiluminescent tracers. J Clin Pathol. 2004,57 (4) :378.
10Pedersen IB, Knudsen N, Perrild H, et al. TSH - receptor antibody measurement for differentiation of hyperthyroidism into Graves' disease and multinodular toxic goiter: a comparison of two competitive binding assays. Clin Endocrinol. 2001,55(3) :381.
